Maze Therapeutics (NASDAQ:MAZE) Shares Up 5.5% – Here’s Why

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s share price rose 5.5% during trading on Monday. The company traded as high as $28.49 and last traded at $29.0450. Approximately 122,329 shares traded hands during trading, a decline of 82% from the average daily volume of 670,087 shares. The stock had previously closed at $27.53.

Analyst Ratings Changes

Several research analysts have issued reports on MAZE shares. Citigroup started coverage on Maze Therapeutics in a research report on Wednesday, September 23rd. They issued a “buy” rating and a $50.00 target price on the stock. Wedbush restated an “outperform” rating and set a $48.00 price target on shares of Maze Therapeutics in a research note on Wednesday, September 23rd. Canaccord Genuity Group initiated coverage on shares of Maze Therapeutics in a research report on Monday. They set a “buy” rating and a $75.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $110.00 price target on shares of Maze Therapeutics in a research report on Thursday, September 24th. Finally, TD Cowen upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Three research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $64.45.

Maze Therapeutics Stock Up 9.3%

The company’s 50 day moving average price is $26.91 and its two-hundred day moving average price is $27.03. The firm has a market cap of $1.80 billion, a PE ratio of -12.88 and a beta of 2.16. The company has a current ratio of 18.31, a quick ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, equities research analysts expect that Maze Therapeutics, Inc. will post -2.70 EPS for the current fiscal year.

Insider Buying and Selling

In other Maze Therapeutics news, insider Atul Dandekar sold 7,500 shares of the business’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $27.58, for a total transaction of $206,850.00. Following the completion of the sale, the insider owned 26,250 shares of the company’s stock, valued at approximately $723,975. The trade was a 22.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Jason V. Coloma sold 34,501 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $26.29, for a total value of $907,031.29. Following the sale, the chief executive officer directly owned 18,151 shares of the company’s stock, valued at $477,189.79. This represents a 65.53% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 192,991 shares of company stock valued at $5,152,084. 5.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Frazier Life Sciences Management L.P. boosted its position in shares of Maze Therapeutics by 10.2% in the second quarter. Frazier Life Sciences Management L.P. now owns 5,032,915 shares of the company’s stock worth $150,182,000 after purchasing an additional 465,641 shares during the period. TRV GP IV LLC purchased a new stake in shares of Maze Therapeutics in the second quarter worth $133,502,907. ARCH Venture Management LLC purchased a new stake in shares of Maze Therapeutics in the second quarter worth $122,983,582. BlackRock Inc. bought a new stake in shares of Maze Therapeutics during the 2nd quarter valued at $104,525,000. Finally, Jupiter Topco LLC bought a new stake in shares of Maze Therapeutics during the 2nd quarter valued at $101,764,000.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc is a biopharmaceutical company focused on developing precision medicines for patients with genetically driven diseases. The company uses human genetics and its proprietary Maze Compass platform to identify disease mechanisms, discover drug targets and design therapies intended to address the underlying biology of serious conditions.

Maze’s pipeline has included small-molecule programs for rare diseases, including MZE001, an investigational glycogen synthase 1 inhibitor being developed for Pompe disease.